LETTERS TO THE EDITOR

Bronchoscopy with bronchoalveolar lavage: determinants of yield and impact on management in immunosuppressed patients

Fibreoptic bronchoscopy with bronchoalveolar lavage (FOB/BAL) is a common modality for the evaluation of pulmonary infiltrates.^{1,2} We recognised there are limitations of comparison between subgroups of immunosuppressed patients, non-uniform definitions of a positive yield, suboptimal description of the impact of concurrent antimicrobial use at the time of the bronchoscopy and sometimes insufficient assessment of management decisions surrounding FOB/BAL.^{3–5} To address these issues, we performed a retrospective analysis of 190 immunosuppressed patients who underwent FOB/BAL for a pulmonary abnormality (clinical or radiographic) at the University of Rochester Medical Center from 2005 to 2008. A positive yield was defined as one of the following: (1) positive culture—bacterial, viral or fungal (not including *Candida albicans* alone); (2) positive finding on cytopathology or fungal stain; or (3) diffuse alveolar haemorrhage. Antimicrobial and corticosteroid treatment changes were assessed 7 days after the bronchoscopy. Bivariate χ^2 analyses were performed using SAS statistical software (SAS Institute, Cary, North Carolina, USA) to determine significance between variables.

A total of 106/190 (55.8%) FOB/BALs had a positive yield. No difference in yield was found on the basis of baseline demographics, type or severity of immunosuppression, severity of illness or positive blood or urine cultures. A positive sputum culture, however, was predictive of a positive yield ($p=0.002$). A total of 37/118 sputum cultures were positive. Twenty-three were concordant with FOB/BAL; however, 35 identified organisms not found on FOB/BAL. Bacteria, fungi and/or viruses were isolated in 4.7, 4.7 and 12.6% of patients who were not on corresponding antimicrobials. Bacteria, fungi and/or viruses that were resistant to concurrent antimicrobials were isolated in 3.6, 2.1 and 10% of patients, respectively.

The duration of treatment doses of antibiotics and the presence of consolidation on chest CT were negatively associated with yield ($p<0.021$ and $p<0.03$); however, consolidation on CT was not associated with a longer duration of antimicrobial treatment ($p=0.252$). If FOB/BAL was performed within 3 days of starting treatment dose antibiotics, the overall yield was 63.4%, but was reduced to 57.6% and 34.4% when performed within 3–14 days or after 14 days, respectively. The use and/or dura-

tion of prophylactic antibiotics, antifungals and/or antivirals did not negatively impact yield.

Seventy-five per cent of patients had treatment altered after FOB/BAL. Overall, 41.5% of patients had antibiotic treatment discontinued or narrowed. Antibiotic coverage was more likely to be narrowed when bacterial cultures were negative ($p=0.003$) and more likely to be broadened if bacterial cultures were positive ($p<0.0001$). Antiviral and antifungal coverages were also more likely to be broadened if viral or fungal cultures were positive ($p=0.008$ and $p=0.003$). The all cause 30-day mortality after FOB/BAL was 16.8%. A positive yield on FOB/BAL did not impact mortality. Furthermore, changes in treatment made on the basis of the bronchoscopy did not significantly impact 30-day mortality.

We found a similar overall yield to previous studies (up to 65%), and we demonstrated that positive sputum cultures were associated with a positive yield on bronchoscopy. It is unclear whether the additional organisms found in the sputum represent upper airway contamination. Furthermore, duration of treatment dose antibiotics for >2 weeks prior to the FOB/BAL and consolidation on CT were important negative predictors of yield. While a positive yield on FOB/BAL was statistically associated with a change in medical management, neither the presence of a positive yield nor changes in treatment were predictive of 30-day mortality.

Ultimately, FOB/BAL is a relatively safe method of obtaining lower respiratory specimens. There were no significant complications directly attributable to the bronchoscopy in our study. While routine bronchoscopy for immunosuppressed patients with pulmonary disease cannot be definitively endorsed on the basis of this study alone, we would suggest FOB/BAL would most optimally be performed within 3 days of the initiation of broad-spectrum antibiotics.

Robert Matthew Kottmann,¹ Jennifer Kelly,² Elizabeth Lyda,³ Michael Gurell,³ Jennifer Stalica,³ Wayne Ormsby,³ Karoline Moon,³ David Trawick,³ Patricia J Sime⁴

¹University of Rochester Medical Center, Division of Pulmonary and Critical Care Medicine, Rochester New York, USA; ²University of Rochester, Department of Community and Preventative Medicine, Rochester, New York, USA; ³University of Rochester, Department of Medicine, Rochester, New York, USA; ⁴University of Rochester, Department of Medicine, Department of Environmental Medicine Rochester, and the Lung Biology and Disease Program, Rochester, New York, USA

Correspondence to Robert Matthew Kottmann, University of Rochester Medical Center, Division of Pulmonary and Critical Care Medicine, 601 Elmwood Avenue, Box 692, Rochester, NY 14642, USA; matt_kottmann@urmc.rochester.edu

Funding Buswell Medicine Fellowship-Department of Medicine, University of Rochester, Rochester, NY; HL-075432; HL-66988; HL 088325; T32 HL066988; NIEHS Center Grant P30ES01247.

Competing interests None.

Ethics approval This study was conducted with the approval of the University of Rochester Medical Center research subjects review board/institutional review board, approval number 22041.

Provenance and peer review Not commissioned; externally peer reviewed.

Accepted 16 July 2010

Published Online First 13 September 2010

Thorax 2011;66:823. doi:10.1136/thx.2010.145540

REFERENCES

1. Azoulay E, Mokart D, Rabbat A, *et al*. Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data. *Crit Care Med* 2008;**36**:100–7.
2. Lehto JT, Koskinen PK, Anttila VJ, *et al*. Bronchoscopy in the diagnosis and surveillance of respiratory infections in lung and heart–lung transplant recipients. *Transpl Int* 2005;**18**:562–71.
3. Shannon VR, Andersson BS, Lei X, *et al*. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2010;**45**:647–55.
4. Kasow KA, King E, Rochester R, *et al*. Diagnostic yield of bronchoalveolar lavage is low in allogeneic hematopoietic stem cell recipients receiving immunosuppressive therapy or with acute graft-versus-host disease: the St. Jude experience, 1990–2002. *Biol Blood Marrow Transplant* 2007;**13**:831–7.
5. Burger CD. Utility of positive bronchoalveolar lavage in predicting respiratory failure after hematopoietic stem cell transplantation: a retrospective analysis. *Transplant Proc* 2007;**39**:1623–5.

British Thoracic Society survey of knowledge of healthcare professionals managing patients with acute hypercapnic exacerbation of chronic obstructive pulmonary disease requiring non-invasive ventilation

The use of non-invasive ventilation (NIV) in acute hypercapnic exacerbations of chronic obstructive pulmonary disease (COPD) is the subject of published guidance from the Royal College of Physicians, the British Thoracic Society (BTS) and the Intensive Care Society, as well as international consensus statements.^{1–3} Although these guidelines have been updated, data from the UK COPD audit detailing admissions to UK hospitals have shown that compliance with this guidance is less than satisfactory.⁴ In part, it has been suggested that the reason for poor implementation of the guidelines is lack of knowledge of indications, technical and practical aspects of delivering NIV by those healthcare professionals assessing, initiating and managing patients. We performed a BTS staff knowledge survey in